Two Sigma Advisers
ZYNE

Two Sigma Advisers’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Two Sigma Advisers’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-124,000
Closed -$40.4K – 2637
2023
Q2 		$40.4K Sell
124,000
-20,900
-14% -$7.49K ﹤0.01% 2285
2023
Q1 		$62.3K Sell
144,900
-41,100
-22% -$21.7K ﹤0.01% 2430
2022
Q4 		$98.6K Sell
186,000
-11,600
-6% -$7.36K ﹤0.01% 2300
2022
Q3 		$145K Buy
197,600
+1,500
+0.8% +$1.7K ﹤0.01% 2259
2022
Q2 		$224K Buy
196,100
+54,500
+38% +$69.4K ﹤0.01% 2242
2022
Q1 		$290K Buy
141,600
+34,100
+32% +$81.1K ﹤0.01% 2235
2021
Q4 		$310K Sell
107,500
-67,800
-39% -$251K ﹤0.01% 2131
2021
Q3 		$743K Buy
175,300
+46,700
+36% +$208K ﹤0.01% 1752
2021
Q2 		$680K Sell
128,600
-39,300
-23% -$189K ﹤0.01% 1807
2021
Q1 		$781K Buy
+167,900
New +$761K ﹤0.01% 1794

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Advisers's ZYNE Position: Q3 2023 in Review

Two Sigma Advisers sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 124,000 shares — an estimated $40.4K sold.

Two Sigma Advisers first reported a position in ZYNE in Q1 2021 and held it in 10 quarters. The position peaked at $781K in Q1 2021. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • Two Sigma Advisers reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 124,000 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $40.4K.
  • Two Sigma Advisers first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 10 quarters.
  • Two Sigma Advisers's Zynerba Pharmaceuticals, Inc position peaked at $781K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.